A GROWING number of randomized controlled trials (RCTs) have evaluated the efficacy of probiotics in patients with IBS. This typically included strains of Lactobacillus or Bifidobacterium species, as well as different probiotic combinations.
Single strain:
Brenner and coworkers conducted a systematic review of 16 RCTs to evaluate probiotics for IBS management1. Bifidobacterium infantis 35624 (Bifantis) was the only one which demonstrated significant improvement in IBS symptoms in appropriately designed RCTs. Studies evaluating single strains of Lactobacillus spp. have generated mixed results2.
Combination probiotics:
VSL #3 is combination of multiple bacteria strains. With a sample size of 48 patients with Rome II IBS, Kim and coworkers found that VSL #3 significantly reduced flatulence scores versus the placebo group3.
Though it is difficult to compare results between studies due to variations in design, probiotic dose and strain, it is important to look for positive clinical evidence when recommending probiotics.
1. Brenner DM et al., Am J Gastroenterol, 2009; 104:1033-49
2. O'Mahony L et al., Gastroenterology, 2005;128:541-51
3. Kim HJ et al., Neurogastroenterol Motil, 2005; 17(5):687-96
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Feb 17
